Yes, Entresto can be given to a patient with an eGFR of 38 mL/min/1.73 m², but the starting dose must be reduced to half the usual dose (24/26 mg twice daily).
Dosing in Moderate Renal Impairment
For patients with eGFR 30-60 mL/min/1.73 m² (moderate renal impairment), no dose adjustment is required for the standard starting dose. However, the FDA label specifies that dose reduction is only mandatory when eGFR falls below 30 mL/min/1.73 m² (severe renal impairment) 1. Your patient with eGFR 38 falls into the moderate impairment category and can start at the usual dose of 49/51 mg twice daily, then titrate up to the target dose of 97/103 mg twice daily 2.
Clinical Evidence Supporting Use
The 2021 ACC Expert Consensus explicitly addresses this scenario: in patients with moderate renal impairment (eGFR ≥30 and <60 mL/min/1.73 m²), no adjustment is needed when deciding the starting dose of sacubitril/valsartan 2. This is reinforced by multiple lines of evidence:
Post-hoc analyses from landmark trials demonstrate that RAAS inhibition benefits are maintained even in patients with baseline CKD, and an initial drop in eGFR of up to 15-20% is expected and represents intra-glomerular hemodynamic changes rather than true nephron loss 3
Recent meta-analysis of 6,217 CKD patients showed sacubitril/valsartan prevented Scr elevation (OR: 0.79,95% CI 0.67-0.95) and reduced >50% eGFR decline compared to ACEi/ARBs 4
Real-world data from 300 Indian patients (51% with CKD) showed stable renal function over 12 months with mean eGFR change of only +2.01 mL/min/1.73 m² 5
Monitoring Requirements
After initiation, you must:
- Check renal function and potassium within 1-2 weeks of starting and after each dose increase 2
- A decrease in eGFR of >30% or development of hyperkalemia should prompt dose reduction, though short-term eGFR changes don't predict long-term adverse outcomes 2
- Continue monitoring every 4 months once stable 6
Expected eGFR Changes
An acute drop in eGFR up to 15-20% after RAAS inhibition initiation is anticipated and transient—this represents beneficial intra-glomerular hemodynamic effects, not kidney damage 3. Analysis from PARADIGM-HF and PARAGON-HF showed that 10-11% of patients experienced >15% eGFR decline during sacubitril/valsartan run-in, but eGFR partially recovered and this decline was not associated with worse outcomes 7. The treatment benefits of sacubitril/valsartan remained consistent regardless of initial eGFR decline 7.
Critical Contraindications to Rule Out
Before prescribing, ensure the patient does NOT have:
- Potassium >5.0 mEq/L (relative contraindication requiring correction first) 2
- Symptomatic hypotension or systolic BP <90 mmHg 2
- History of angioedema with ACEi/ARB (absolute contraindication) 1
- Current ACEi use within 36 hours (must have washout period) 1
Practical Titration Strategy
- Start at 49/51 mg twice daily (standard dose for eGFR 30-60)
- Check labs at 1-2 weeks: if K+ <5.5 and eGFR decline <30%, proceed
- Uptitrate to 97/103 mg twice daily at 2-4 weeks if tolerated
- If eGFR drops >30% or K+ rises >5.5 mEq/L: halve the dose and recheck labs closely 6
- Do not discontinue for mild eGFR decline alone—the long-term renal and cardiovascular benefits outweigh transient changes 3, 7
Common Pitfall to Avoid
The most frequent error is withholding or under-dosing RAAS inhibitors due to fear of worsening renal function 3. Renal dysfunction is one of the most reported reasons for under-dosing guideline-directed therapy, yet the evidence clearly shows that benefits persist even with baseline CKD and initial eGFR decline 3. Understanding that a small reduction in eGFR is expected and beneficial—not harmful—is essential for optimal heart failure management 3.
The 2022 ADA/KDIGO consensus reinforces that ACEi/ARB continuation as kidney function declines to eGFR <30 may provide cardiovascular benefit without significantly increasing risk of end-stage kidney disease 8, further supporting aggressive use of RAAS blockade in this population.